Improving hormonal therapy: to extend, to intermit, or to readjust expectations?

Iris Noordhoek, Esther Bastiaannet, Cornelis J. H. van de Velde


For quite some time now, a discussion has been going on in the world of breast cancer research concerning the optimal duration of hormonal therapy (HT) in hormone receptor (HR) positive early breast cancer. Multiple trials have tried providing closure to this discussion, but so far, none have succeeded (1).